Anixa Biosciences, Inc. (ANIX) Completes 5th CAR‑T Cohort; No DLTs, Stable Disease Seen
Meno di 1 minuto di lettura
Anixa completed dosing of the fifth cohort in its Phase 1 FSHR‑targeted CAR‑T trial for recurrent ovarian cancer, reporting no dose‑limiting toxicities to date and stable disease at 90 days in the first patient of the cohort. Four patients have survived beyond one year, one beyond two years.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | 5th cohort dosing completed | Keeps trial on track; de-risks execution and supports advancing to higher dose. |
| 2 | No DLTs observed to date | Favorable safety supports dose escalation and potential broader dosing. |
| 3 | Stable disease at 90 days | Early efficacy signal in heavily pre-treated ovarian cancer. |
| 4 | 4 patients >1 year survival | Suggests durability signals versus typically poor prognosis. |
| 5 | One patient >2 years survival | Outlier durability may indicate meaningful clinical activity. |
| 6 | Next: escalate to 1×10^8 cells/kg | Higher dose could enhance response; safety read-in due after 30 days. |
Context by AI Analyst
This is an early-stage Phase 1 safety and dose-escalation update with preliminary efficacy signals in a hard-to-treat setting. A larger catalyst would be confirmed responses at higher doses, formal ORR/DCR data, and a clear path to Phase 2 after safety verification.
Based on the original press release from Anixa Biosciences, Inc. distributed by PR Newswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by PR Newswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.
© Copyright 2026 Cision US Inc. All Rights Reserved.